DJIA 17,086.63 -26.91 -0.16%
NASDAQ 4,473.70 17.68 0.40%
S&P 500 1,987.01 3.48 0.18%
market minute promo

Vertex Pharmaceuticals (NASDAQ: VRTX)

98.14 0.40 (0.41%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

VRTX $98.14 0.41%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $97.74
Previous Close $97.74
Daily Range $97.44 - $98.61
52-Week Range $58.06 - $99.74
Market Cap $23.2B
P/E Ratio -63.06
Dividend (Yield) $0.00 (0.0%)
Volume 1,454,427
Average Daily Volume 2,935,234
Current FY EPS -$2.67

Sector

Healthcare

Industry

Drugs

Vertex Pharmaceuticals (VRTX) Description

The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Website: http://www.vrtx.com/

News & Commentary Rss Feed

3 Things to Watch at Gilead

Hepatitis C is important, but only for two of the thee points.

Vertex Is Poised For An Earnings Breakout

Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data - Anal

Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data - Analyst Blog

Fed: Beware of social media, biotech stocks

Nasdaq 100 Movers: VRTX, MYL

Vertex Pharmaceuticals Inc Stock Upgraded (VRTX)

Vertex Pharmaceuticals Inc. (VRTX): New Analyst Report from Zacks Equity Research - Zacks Equity Res

Vertex Pharmaceuticals Inc. (VRTX): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

Merck, Gilead Lead Race To Eradicate Hepatitis C

Vertex Pharmaceuticals Up on Kalydeco sNDA Submission - Analyst Blog

Vertex Pharmaceuticals Up on Kalydeco sNDA Submission - Analyst Blog

Biotech Stock Roundup: Vertex Jumps on Phase III Data, MannKind Scores FDA Approval - Analyst Blog

Cramer's Mad Money - The Mother Of All Speculative Stocks (7/1/14)

See More VRTX News...

VRTX's Top Competitors

VRTX $98.14 (0.41%)
Current stock: VRTX
AMGN $122.01 (0.74%)
Current stock: AMGN
GILD $90.34 (1.13%)
Current stock: GILD
BIIB $337.60 (11.17%)
Current stock: BIIB